# A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects

> **NCT03056326** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 72 (actual)

## Conditions studied

- Non-Cystic Fibrosis Bronchiectasis
- Cystic Fibrosis

## Interventions

- **DRUG:** CHF6333 (Part 1 - SAD)
- **DRUG:** Placebo (Part 1 - SAD)
- **DRUG:** CHF6333 (Part 2 - MAD)
- **DRUG:** Placebo (Part 2 - MAD)

## Key facts

- **NCT ID:** NCT03056326
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03056326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03056326, "A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03056326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*